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ABSTRACT
Objective: To explore the possible misexpression of the microRNA miR-196b in 
colorectal cancer (CRC) and its role in controlling the expression of GATA6, a putative 
target gene crucial to intestinal cell homeostasis and tumorigenesis.
Design: The expression of miR-196b was analysed by qRT-PCR in surgical 
resection samples from a cohort of sporadic colon cancer patients. Manipulations of 
miR-196b expression were performed to demonstrate its inhibition of GATA6 protein 
levels.
Results: We found that miR-196b is significantly upregulated in pre-treatment 
surgical resection samples from a cohort of sporadic colon cancer patients. 
The upregulation of miR-196b correlates with less severe clinicopathological 
characteristics, such as early tumor stage and absence of lymph node metastases. 
We show that in CRC cells, miR-196b targets the mRNA of GATA6, a transcription 
factor involved in the homeostasis and differentiation of intestinal epithelial cells, 
and a positive regulator of the Wnt/β-catenin pathway. We moreover found that the 
increase of miR-196b correlates with a reduced GATA6 protein expression in colon 
cancer patients.
Conclusion: Our results establish miR-196b as a post-transcriptional inhibitor of 
GATA6 in CRC cells, implicating miR-196b function in gene regulatory pathways crucial 
to intestinal cell homeostasis and tumorigenesis. Our results furthermore suggest a 
role of miR-196b expression in CRC, as an antagonist of GATA6 function in tumor cells, 
thus providing the basis for a potential targeting strategy for the treatment of CRC.
INTRODUCTION
MicroRNAs (miRNAs) are involved in the 
regulation of a wide array of biological processes, 
ranging from cell cycle regulation to differentiation 
and development. Accordingly, the deregulation of 
miRNA expression has been implicated in several 
human diseases, including cancer [1]. While miRNA 
misregulation is recurrent in human cancer, for many 
malignancies it is still unknown whether the altered 
expression of miRNAs affects gene regulatory networks 
involved in the pathogenesis, and in this case, whether it 
is causative, correlative, or protective. miRNAs are small 
non-coding RNAs of ~20-24 nucleotides (nt) in length, 
which negatively control gene expression at the post-
transcriptional level. They derive from larger primary 
miRNAs (pri-miRNAs), in many cases non-coding, which 
are processed by endonucleases to nuclear precursors (pre-
miRNAs), and eventually to their mature cytoplasmic 
form. miRNAs typically bind to the 3' UTR of their target 
mRNAs, and either inhibit translation or induce mRNA 
degradation [2, 3].
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miR-196 family members have been reported 
to participate in relevant biological processes, such as 
embryonic development (reviewed in 4) and tumorigenesis, 
where they have been found to be aberrantly expressed in 
various malignancies, including glioblastoma, colorectal 
cancer, melanoma, and leukemia (reviewed in 5). We 
recently reported the characterization of the miR-196b 
promoter. miR-196b is one of the three members of the 
evolutionarily conserved miR-196 gene family, which 
includes in addition miR-196a-1, miR-196a-2, all located 
within the HOX gene clusters [6]. We reported that the 
evolutionarily conserved genomic region upstream to 
the pri-miR-196b transcriptional start site (TSS) contains 
several binding sites for Cdx and 5'Hox transcription 
factors, that these sites are bound in vivo by Cdx2, and that 
Cdx2 is necessary for the expression of miR-196 in human 
embryonal carcinoma (EC) cells, establishing Cdx2 as a 
major regulator of miR-196b expression [7]. The Caudal-
related homeobox transcription factor 2 (CDX2) gene 
is crucial for the normal development of the intestinal 
tract and for intestinal epithelium homeostasis [8–10]. In 
adult human, CDX2 expression is confined to the small 
intestine and colon [11], and in colon cancer it has been 
proposed as a tumor suppressor gene [12–14]. Colorectal 
cancer (CRC) is worldwide the third most common cancer 
and the second major cause of cancer-related death [15]. 
Evidence has been increasing in the past years that CRC is 
a heterogeneous disease, whose molecular features decide 
the response to treatment and hence the prognosis [16].
Given the regulation of miR-196b by CDX2, a 
transcription factor important to intestinal epithelial 
cell homeostasis and disease, in this work, we wanted 
to explore the possible misregulation of miR-196b in 
colorectal cancer. We moreover wanted to verify whether 
miR-196b would control the expression of GATA6, 
a transcription factor involved in intestinal epithelial 
cell proliferation and CRC, which was predicted in 
silico as a target gene for miR-196b. GATA6 codes for 
a member of the GATA family of transcription factors. 
GATA transcription factors play relevant roles in the 
development, proliferation, and differentiation of several 
organs [17, 18], of these GATA4, 5 and 6 are expressed 
in many tissues including the gastrointestinal tract [19]. 
More specifically, the GATA6 gene is expressed in all the 
gastrointestinal epithelium with a peak of expression in 
the proliferative compartment of the crypts [20–22]. In 
accordance, the targeted inactivation of GATA6 in mice 
causes early lethality due to the absence of endoderm 
differentiation [23, 24]. GATA6 has been shown to be 
misregulated in colon cancer cells, suggesting a relevant 
role for GATA6 in the onset and progression of colon 
cancer [25, 26]. Indeed, GATA6 has been found to be 
a key player in a regulatory network converging into a 
pathway crucial to colorectal tumorigenesis, the Wnt/β-
catenin signalling pathway [27].
Our results establish GATA6 as a target of miR-196b 
in colon cancer cells. We furthermore show that miR-196b 
is significantly upregulated in a cohort of sporadic colon 
cancer patients. Its upregulation was found to correlate 
with early stages of disease progression and with a marked 
reduction in GATA6 expression in colon cancer samples. 
Our results point to a regulatory mechanism, which could 
represent a potential target for the therapy of CRC.
RESULTS
miR-196b expression is upregulated in human 
colon cancer
As miR-196b was found [7] to be directly activated 
by the CDX2 intestinal-specific transcription factor [11], 
implicated in colon cancer pathogenesis [12–14], we 
sought to determine whether miR-196b expression was 
misregulated in colorectal cancer (CRC). To this end, we 
analysed the expression of miR-196b in intestinal tissue 
samples from a cohort of 63 colon cancer patients (see 
Table 1). The expression of miR-196b was determined 
by qRT-PCR on total RNA extracted from pre-
treatment surgical resection samples of tumor mass and 
corresponding adjacent normal mucosa.
The expression of miR-196b was found to be 
significantly upregulated, with respect to paired normal 
adjacent tissue, in 40/63 (63.5%) of the colon cancer 
samples (Figure 1A). We then sought to correlate the 
misexpression of miR-196b in colon cancer samples with 
the clinicopathological characteristics of our cohort of 
patients. The misexpression of miR-196b was significantly 
associated to tumor grade. Grade 3 tumor samples showed 
an increase in miR-196b expression with respect to paired 
normal adjacent tissue, while grade 1 samples did not 
display a significant miR-196b upregulation (Figure 1B). 
miR-196b misexpression was moreover found to correlate 
with tumor stage, as the majority of colon cancer samples 
showing miR-196b upregulation belonged to the group 
of stage I and II tumors with respect to samples of the 
stage III and IV group (Figure 1C). A correlation was 
found in addition regarding lymph node metastases. miR-
196b upregulation was significantly associated with the 
absence of lymph node invasion (N0) (Figure 1E). Finally, 
miR-196b misexpression also correlated with the site of 
origin of the primary tumor. The majority of samples 
showing miR-196b upregulation were derived from left 
colon (Figure 1F). No significant associations were found 
with the depth of tumor invasion (T) (Figure 1D) and with 
gender (Figure 1G), as well as with the diameter of the 
tumor mass and the age of the patients (Supplementary 
Figure S1)
Thus, collectively, our data show that miR-196b 
expression is significantly upregulated in colon cancer 
and that miR-196b upregulation is associated to several 
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relevant clinicopathological features, such as tumor grade, 
stage and lymph node invasivity, suggesting that miR-
196b misexpression may play a role in CRC pathogenesis 
by modulating the expression of target genes relevant to 
intestinal epithelial cell proliferation and/or differentiation.
The GATA6 transcription factor is a target of 
miR-196b
We then searched for potential targets for the 
regulation by miR-196b that would be relevant to intestinal 
development and/or to CRC. Using the Targetscan, 
miRDB, PicTar, and DIANA-TarBase (see Materials and 
Methods) search platforms we identified the GATA6 gene 
as a candidate miR-196b target gene. GATA6 is a member 
of the GATA family of transcription factors, which play 
relevant roles in the development and differentiation 
of several organs, including the gastrointestinal tract 
[19]. The 3' untranslated region (3'UTR) of the GATA6 
mRNA contains a single target sequence for miR-196b, 
5'-TGCAACAACACTTTACTACCTA-3', located 
approximately at the center of the 3'UTR (Figure 2A). 
The GATA6 miR-196b target sequence showed an 8mer 
seed match with a context++ score percentile of 99 and a 
total context++ score of -0.60 (Targetscan), and the target 
sequence was found to be evolutionarily highly conserved 
among land vertebrates (Figure 2C). We thus sought to 
confirm whether GATA6 is indeed negatively regulated by 
miR-196b. To this end we employed a luciferase reporter 
assay.
Three different luciferase reporter constructs 
were generated (Figure 3A), one containing the wild 
type GATA 3' UTR region (pL-G6-3'UT), ranging 
approximately from the GATA6 stop codon to the 
GATA6 mRNA polyadenylation site (see Figure 2A), 
another containing the same GATA 3' UTR region, but 
carrying a mutation of the miR-196b target sequence 
(pL-G6-3'UTm, Figure 3A), and a third one containing 
one copy of the Hoxb8 miR-196b target sequence as a 
positive control [28] (pL-196TS, Figure 3A). These 
reporter constructs were transfected, together with 
the mature miR-196b (miR-196b-5p, Ambion), with a 
control unrelated miRNA (Ambion), or with the control 
miR-196b-3p opposite strand miR-196b, in P19 murine 
embryonal carcinoma cells, or in HCT116 and HT29 
human colon cancer cells. In P19 cells, which express 
very low levels of endogenous miR-196b and GATA6 
(Supplementary Figure S2), the exogenous administration 
of mature miR-196b (miR-196b-5p) caused a significant 
decrease of the activity of the pL-G6-3'UT reporter, to 
Table 1: Clinicopathological parameters of colon cancer patients
Clinical parameter N. of patients (n=63)
Tumor Grade
 Grade 1 18
 Grade 3 45
TNM Stage
 I - II 35
 III - IV 28
Tumor Depth
 T 1-2 13










* = Descending + sigmoid
** = Ascending + transverse
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Figure 1: Expression of miR-196 in colon cancer human samples. A. Relative expression of miR-196b vs RNU6B in matched 
healthy mucosae (light grey) and their corresponding primary colon cancer samples (dark grey) in aligned dot plot (left panel) and before-
after (right panel) charts. In before-after graphs, patients with upregulated miR-196b expression in cancer lesions are indicated with circles 
and connected with a dark dashed line. Patients' samples with downregulated miR-196b are represented with triangles and connected by 
light dashed line. B-G. Aligned dot plot charts of patients classified according to the following tumor parameters: grade (B), stage (C), depth 
(D), lymph node metastasis (E), site of primary tumor (F) and gender (G). Bold horizontal bars represent mean expression level ± SEM. N 
= healthy mucosa. C = primary cancer. NS = not significant. * = p<0,05. ** = p<0,01. *** = p<0,001; paired t-test.
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~68% with respect to pL-G6-3'UT cotransfected with 
the control miRNA, and to ~64% with respect to pL-
G6-3'UT cotransfected miRNA processed from the 
opposite strand of the miR-196 precursor (miR-196b-3p) 
(Figure 3B). A comparable reduction was observed with 
the pL-196TS positive control (Figure 3B). Similarly, 
in HCT116 colon cancer cells, the activity of the pL-
G6-3'UT and the pL-196TS reporters was significantly 
reduced by cotransfection of miR-196b-5p, to ~60% with 
respect to pL-G6-3'UT or pL-196TS cotransfected with 
the control miRNA and complementary miRNA (miR-
196b-3p) (Figure 3C). Also in HT29 colon cancer cells 
miR-196b-5p transfection led to a decrease of pL-G6-
3'UT and pL-196TS reporter activity, albeit to a lesser 
extent with respect to HCT116 cells, probably because of 
the higher expression levels of endogenous miR-196b and 
GATA6 (see Supplementary Figure S2) (Figure 3D). No, 
or only minor reductions of the reporter activities were 
observed with the control and miR-196b-3p miRNAs and 
with the mutated pL-G6-3'UTm reporter (Figure 3D).
Taken together, these results show that the GATA6 
3'UTR can be targeted by miR-196b both in murine 
embryonal carcinoma as well as in human colon cancer 
cells.
miR-196b exogenous expression decreases 
endogenous GATA6 protein levels in colon 
cancer cells
We next wanted to further substantiate the regulation 
of GATA6 by miR-196b by verifying whether miR-196b 
overexpression would cause a decrease in cellular GATA6 
protein. We thus transfected HCT116 and HT29 colon cancer 
cells, which express endogenous GATA6 (Supplementary 
Figure S2B), with the mature miR-196b (miR-196b-5p, 
Ambion), with a control, unrelated miRNA (Ambion), or with 
the control, opposite strand miR-196b-3p in HCT116 cells. 
miR-196b-5p overexpression caused a substantial decrease of 
endogenous GATA6 protein as revealed by immunoblotting 
(Figures 4A and 4C). Conversely, no changes in cellular 
GATA6 amounts were observed in mock-transfected cells, 
and in cells transfected with the control and miR-196b-3p 
miRNAs (Figures 4A and 4C). Similarly, in HT29 cells, 
GATA6 protein expression was significantly reduced only by 
cotransfection of miR-196b-5p, and not by cotransfection of 
the control and miR-196b-3p miRNAs (Figures 4B and 4D). 
In the same experiments, no significant changes in mRNA 
levels of GATA6 were observed both in HCT116 (Figure 4E) 
and HT29 (Figure 4F) colon cancer cells.
Figure 2: The 3’UTR sequence of GATA6 contains a conserved miR-196b target site. A. Schematic representation of the 
human GATA6 3’ untranslated (3’UTR) region. Sequence positions are indicated, considering ‘+1’ the transcriptional start site (TSS) of the 
GATA6 transcript. TS, miR-196b target site. B. Interaction between miR-196b and the target site annotated on the 3’UTR of GATA6, as 
predicted by Targetscan software. C. Sequence comparison of the miR-196b target site. Dark grey boxes indicate the interaction mediated 
by the seed-region whereas the light rectangle indicates an additional pairing site driven by the 3’ half of miR-196b. The indicated species 
are: Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus, Anolis caroliniensis, Danio rerio, Xenopus tropicalis.
Oncotarget4752www.impactjournals.com/oncotarget
We then tested, using an anti-miR-196b antagomir, 
whether, reciprocally, a reduction of endogenous miR-
196b would cause an increase in GATA6 protein levels. 
HCT116 cells, transfected with the anti-miR-196b 
antagomir showed a ~80% increase in GATA6 protein 
with respect to non-transfected or mock-transfected cells 
(Figure 4G-4H). Together, these results establish GATA6 
as a target of miR-196b in colon cancer cells.
To test whether miR-196b exogenous expression 
would affect the proliferation and the cell cycle of 
colon cancer cells, HCT116 cells were transfected with 
the mature miR-196b (miR-196b-5p, Ambion), with a 
control, unrelated miRNA (Ambion), and cells were 
counted at different time points to measure the increase 
in vital cell numbers. Total protein extracts were also 
prepared to analyse phospho-Histone H3(Ser10) content 
by immunoblotting. Interestingly, the exogenous, transient 
expression of miR-196b, despite a detectable reduction in 
GATA6 protein levels, led to a slight, but reproducible 
increase in the cell growth rate and an initial increment 
in phospho-H3(Ser10) with respect to the exogenous 
expression of a control, unrelated miRNA (Supplementary 
Figure S3). However, at later timepoints, the fraction of 
mitotic cells, as revealed by phospho-H3(Ser10) amounts, 
decreased concomitantly with the decrease of GATA6 
levels (Supplementary Figure S3C).
The cycle of HCT116 cells expressing exogenously 
miR-196b was also analysed, using monovariate and 
bivariate flow cytometry (Supplementary Figure S4). 
The expression of miR-196b caused an increase in the 
fraction of HCT116 cells in G2/M phase with respect to 
cells transfected with the control miRNA at 120 hrs after 
miR-196b transfection (Supplementary Figure S4A). 
No significant effects on the HCT116 cell cycle were 
observed in cells transfected with a control, unrelated 
miRNA (Supplementary Figure S4A). Also no significant 
changes in the fraction of apoptotic cells were observed 
(Supplementary Figure S4A). Bivariate analysis of DNA 
Figure 3: miR-196b functionally interacts with the GATA6 3’UTR. A. Schematic representation of the reporter constructs used 
in luciferase transfection assays. SV40, SV40 early promoter. pA, SV40 late poly-adenylation signal. Luciferase activities assayed in cell 
extracts of P19 murine cells B., HCT116 and HT29 human CRC cells (C and D, respectively), transiently transfected with 200ng of the 
reporter constructs listed in (A) together with the synthetic microRNAs (40nM) indicated below. Bars represent the mean luciferase activity 
± SEM of at least three independent experiments. * = p<0,05. ** = p<0,01. *** = p<0,001; non-parametric Kruskal-Wallis test followed by 
the Dunn’s post-hoc test. CT, scrambled unrelated oligonucleotide. 5p, miR-196b-5p; 3p, miR-196b-3p
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content and BrdU uptake showed, at 120 hrs after miR-
196b transfection, an increase in the fraction of cells 
in late S phase with respect to cells transfected with a 
control, unrelated miRNA (Supplementary Figure S4B), 
suggesting a delay in the progression towards G2/M phase. 
Together, these results suggest that miR-196b exogenous 
expression alters both endogenous GATA6 protein levels 
and the proliferation and cell cycle of HCT116 cells.
miR-196b expression increases upon colon cell 
differentiation concomitantly with a decrease of 
GATA6 protein levels
In an attempt to clarify the possible role(s) of miR-
196b expression, and of its control over GATA6 protein 
levels, in colon cell physiology, we investigated whether 
variations of the expression of miR-196b would correlate 
Figure 4: miR-196b expression reduces GATA6 protein levels. Immunoblot analysis showing GATA6 levels in HCT116 
(A) and HT29 (B) human CRC cells transfected with the indicated mature synthetic microRNAs. CT, scrambled oligonucleotide. 196b-5p, 
miR-196b-5p; 196b-3p, miR-196b-3p; MK, mock-transfected; NT, non transfected control. β-actin was used as loading control. Scanning 
densitometry of immunoblottings of HCT116 and HT29 cells (C, D, respectively). GATA6 mRNA levels assayed by qRT-PCR in total RNA 
from transfected HCT116 (E) and HT29 (F) cell lines. Expression levels were calculated according to the ΔΔCt method using the ribosomal 
protein L19 (RPL19) mRNA as a reference control. Immunoblot analysis showing GATA6 levels in HCT116. (G) HCT116 cells transfected 
with the microRNA antagomirs indicated below. CT, scrambled antagomir; Anti-196b, miR-196b-5p antagomir. Bars represent the mean ± 
SEM of at least three independent experiments.
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with the differentiation of intestinal epithelial cells. To this 
end, we used Caco-2 cells, a human colon adenocarcinoma 
line, which undergoes spontaneous differentiation in 
culture displaying numerous differentiation hallmarks of 
intestinal epithelial cells [29, 30], and hence appeared to us 
as a profitable cell model to study colon cell differentiation 
in culture.
Caco-2 cells were seeded at low density and 
cultured for three weeks; after reaching confluency they 
were collected at different time points to prepare nuclear 
extracts. Cycling Caco-2 cells displayed high levels 
of GATA6 protein as determined by immunoblotting 
(Figure 5D, see also Supplementary Figure S2B), which 
correlated with low levels of miR-196b expression 
(Figure 5A, see also Supplementary Figure S2A). 
During the first 7 days of differentiation GATA6 levels 
gradually declined to reach ~52% of the amount observed 
in cycling cells (Figure 5C-5D). In the following 14 
days GATA6 levels continued to decline, reaching after 
21 days their minimum, corresponding to ~36% of the 
amount observed in cycling cells (Figure 5C-5D). In 
parallel, miR-196b expression showed an 8-fold increase 
throughout the culturing time, reaching its maximal level 
at 21 days of culture (Figure 5A). We also verified possible 
variations in GATA6 mRNA levels by qRT-PCR during the 
differentiation of Caco-2 cells, and observed no significant 
changes in GATA6 transcript amounts, even after 21 days 
of culture (Figure 5B).
Thus, these data show that the steady increase of 
miR-196b expression corresponds to a steady decrease 
of GATA6 protein levels, which is not paralleled by a 
decrease in GATA6 mRNA levels, further supporting 
the idea that GATA6 expression is controlled post-
transcriptionally by miR-196b. Of note, the increase 
Figure 5: miR-196B and GATA6 expression levels inversely correlate during in vitro intestinal differentiation. Caco-2 
adenocarcinoma cells were induced to differentiate towards an enterocyte identity for 21 days upon confluency. miR-196b A. and GATA6 
mRNA B. expression levels assayed by qRT-PCR in total RNA from differentiating Caco-2 cells. Expression levels were calculated 
according to the ΔΔCt method using RNU6B and RPL19, respectively, as reference genes. Scanning densitometry C. and immunoblotting 
D. of GATA6 protein during Caco-2 differentiation. Protein levels were normalized against β-actin expression. CDX2 protein was used 
as a marker of in vitro intestinal differentiation. CICL, cycling cells. ACTB, beta-Actin. Bars represent the mean ± SEM of at least three 
independent experiments. ** = p<0,01; one-way ANOVA followed by the Bonferroni’s multiple comparison test.
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of miR-196b expression accompanying Caco-2 cell 
differentiation also correlated with the concomitant 
increase of expression of CDX2, a transcription factor, 
which we previously identified as being a regulator of 
miR-196b transcription, and is a differentiation marker of 
intestinal cells [7].
GATA6 protein levels are reduced in tissue 
samples from colon cancer patients showing 
miR-196b upregulation
We next wanted to verify whether the upregulation 
of miR-196b expression correlated with a reduction in 
GATA6 expression in colon cancer tissue samples. To 
this end, we selected tissue samples showing miR-196b 
upregulation, and determined GATA6 protein expression 
by immunohistochemistry. Nine out of ten tissue samples 
(90%) displaying miR-196b upregulation showed a 
marked decrease in GATA6 protein levels in tumor tissue 
with respect to the adjacent normal colonic mucosa 
(representative results are shown in Figure 6, panels 
A to F). One sample having a miR-196b upregulation 
(~2-fold) displayed instead a more intense GATA6 
expression in tumour tissue than in normal colonic mucosa 
(Figure 6, panels G and H).
These results confirm that miR-196b upregulation 
correlates with a reduction in GATA6 protein levels in 
colon cancer tissue samples.
DISCUSSION
miR-196 family members have been shown to 
participate in important biological processes, such 
as embryonic development [4] and tumorigenesis, 
where they have been found to be misexpressed in 
various malignancies [5]. We recently reported the 
characterization of the miR-196b promoter and established 
the CDX2 transcription factor as a major regulator of 
miR-196b expression [7]. The CDX2 gene is crucial for 
the normal morphogenesis of the intestinal tract and for 
intestinal epithelium homeostasis [8–10], and in adult 
human its expression is confined to the small intestine 
and colon [11]. In colorectal cancer (CRC) CDX2 it has 
been proposed as a tumor suppressor gene [12–14]. In 
this study, we therefore wanted to explore the possible 
involvement of miR-196b in CRC, by verifying at first 
whether it was misregulated in pre-treatment surgical 
resection samples from colon cancer patients. Our results 
show that miR-196b is indeed upregulated in the tumor 
mass of the majority of colon cancer samples analysed. 
We found in addition that the upregulation of miR-196b 
significantly correlates with several clinicopathological 
characteristics, such as tumor grade, stage, and lymph 
node metastases. Notably, miR-196b upregulation reveals 
in general to correlate with less severe clinicopathological 
characteristics, such as stage I/II of the disease and the 
absence of lymph node metastases, with the only possible 
Figure 6: Protein levels of GATA6 are down-regulated in colon cancer tissues. Expression of GATA6 in the normal colonic 
epithelium (A: C: E: G) and primary colon cancer (B: D: F: H) was detected by IHC. The positive staining was counterstained with 
hematoxylin. Images are representative of n=10 patients. Scale bar = 200 μm.
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exception of tumor grade, as miR-196b was found to be 
upregulated preferentially in grade 3 colon cancer samples.
In trying to understand which one(s) among the 
numerous predicted targets of miR-196b could play 
a role in the pathogenesis of CRC, our attention was 
attracted by the GATA6 transcription factor. Members 
of the GATA family of Zn-finger transcription factors 
play important roles in the control of cell proliferation 
and differentiation in several tissues and organs [17, 18]. 
GATA6, in particular, is expressed in the proliferating 
cells of the intestinal crypts and was shown to be required 
for crypt cell proliferation and migration [20, 21], and its 
targeted inactivation in mice causes early lethality due to 
a failure in endoderm differentiation [23, 24]. GATA6 has 
been shown to be misexpressed in CRC cells from the 
earliest stages of dysplasia continuing to late metastatic 
lesions, pointing to a crucial role in the pathogenesis and 
progression of colon cancer [25, 26]. In accordance, in a 
nude mouse xenograft model, the tumorigenicity of CRC 
cells has been shown to be blocked by a knocking down 
GATA6 [27, 31].
Being GATA6 an in silico predicted target of miR-
196b, we decided to verify whether it was indeed inhibited 
by miR-196b and whether miR-196b upregulation would 
reduce GATA6 protein levels in CRC cells. We found 
that a target sequence for miR-196b, located within the 
3'UTR of the GATA6 mRNA is necessary for mediating 
post-transcriptional regulation of GATA6 expression by 
miR-196b. In CRC cells, endogenous GATA6 protein 
levels were found to be downregulated by miR-196b 
overexpression, and in the Caco-2 intestinal epithelial 
cell differentiation model, the decrease in GATA6 
protein expression during differentiation correlated with 
an upregulation of miR-196b expression. Our results 
thus establish GATA6 as a target of miR-196b post-
transcriptional regulation in CRC cells, implicating miR-
196b function in gene regulatory pathways crucial to 
intestinal cell homeostasis and tumorigenesis. GATA6 
is in fact a positive regulator of a set of genes relevant 
to CRC carcinogenesis and progression, such as uPA, 
REG4 [26, 31], and most importantly LGR5 [27]. LGR5 
is an R-spondin receptor, which has been identified as a 
marker of the intestinal crypt basal columnar stem cells 
[32]. LGR5 is a target gene of the canonical Wnt/β-catenin 
signalling pathway, and at the same time potentiates Wnt/
β-catenin signalling by enhancing Wnt-induced LRP6 
phosphorylation [33]. Thus GATA6, by controlling the 
transcription of LGR5, positively impacts on Wnt/β-
catenin signalling in intestinal epithelial stem cells [27].
The vast majority of colorectal cancers (~90%) carry 
mutations in one of two genes involved in the canonical 
Wnt/β-catenin signalling pathway: the adenomatous 
polyposis coli (APC) and -catenin (CTNNB1) genes. More 
than 80% of colorectal cancers have mutations in the APC 
tumor suppressor gene. Mutation of the-catenin gene is 
mutually exclusive to APC mutation, and about half of all 
CRCs with wild-type APC have mutations in the CTNNB1 
gene [34]. Experimental evidence has been accumulating 
that intestinal tumorigenesis is caused by the aberrant 
activation of Wnt/β-catenin signaling in epithelial stem 
cells [32]. It has been furthermore recently shown that the 
restoration of APC function causes established colorectal 
cancer to revert to normal epithelia, even in the presence 
of mutations in the Tp53 and Kras genes, demonstrating 
the dependency of CRC cells on constitutively active Wnt 
signaling [35].
The negative regulation of GATA6 expression by 
miR-196b likely impinges on Wnt/β-catenin signaling 
via the downregulation of LGR5 transcription. A similar 
control has been reported to be exerted by miR-363, which 
was found to target the GATA6 mRNA and to cause a 
decrease in the tumorigenicity of CRC cells [27]. miR-
363, however, unlike miR-196b, has been shown to be 
downregulated in CRC tissue samples [27]. We propose 
that the upregulation of miR-196b, which we observed in 
CRC tissue samples and found to correlate with a reduction 
of GATA6 protein levels, could represent a putative 
protective response of CRC cells to the aberrant activation 
of Wnt/β-catenin signaling. Indeed, miR-196 family 
members, including miR-196b, have been reported to act 
as metastasis suppressors in breast cancer cells, being their 
enforced expression able to inhibit cell invasion in vitro 
and metastasis formation in vivo [36]. Interestingly, we 
found that the exogenous expression of miR-196b in 
HCT116 colon cancer cells, despite causing a detectable 
decrease in GATA6 protein levels, slightly increases 
cell proliferation and, initially, the fraction of mitotic 
cells. Mitotic cells, however, subsequently decrease 
concomitantly with the further reduction in GATA6 levels. 
The relatively moderate and delayed effect of miR-196 
exogenous expression could rest on the transient mode of 
expression of miR-196 within cells. Alternatively, the mild 
effect of miR-196 exogenous expression on HCT116 cell 
proliferation could rest on mechanisms other than GATA6 
downregulation. Further work will be required to highlight 
the effect of miR-196b upregulation on LGR5 expression, 
on Wnt/β-catenin signaling, and on tumorigenicity in CRC 
cells. Nevertheless, the findings that GATA6 expression 
is significantly reduced in tissue samples showing 
upregulation of miR-196b and that miR-196b upregulation 
correlates with less severe clinicopathological features 
would suggest a possible protective role of miR-196b 
upregulation in CRC carcinogenesis.
MATERIALS AND METHODS
Patients
Formalin-fixed, paraffin-embedded (FFPE) primary 
cancer tissues and matched colonic mucosae from 63 colon 
cancer patients were analyzed. All cases were enrolled at 
the Policlinico Universitario of Modena hospital, Modena, 
Oncotarget4757www.impactjournals.com/oncotarget
Italy. Only patients affected by sporadic colon cancer 
samples were included in this study and patients treated 
with radio- or chemo-therapy prior to surgery together 
with patients affected by mucinous cancer were excluded. 
All the cases were collected between 2008 and 2014.
Cell culture and cell cycle analyses
P19 cells (ATCC# CRL-1825) mouse embryonal 
carcinoma cells were cultured in Minimum Essential 
Medium Alpha (αMEM, GIBCO), with nucleosides. 
Caco-2 (ATCC# HTB-37) and HT29 (ATCC# HTB-38) 
human colorectal adenocarcinoma cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM, 
Euroclone). HCT116 (ATCC# CCL-247) human 
colorectal carcinoma cells were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM, Euroclone). All 
the media were supplemented with 10% foetal bovine 
serum, 2mM L-glutamine, 100U/mL penicillin and 100 
μg/mL streptomycin. For in vitro differentiation assays, 
Caco-2 cells were cultured for 21 days after they reached 
confluence [37]. Medium was replaced three times a 
week. Cell growth was assessed using the trypan blue 
dye exclusion staining and cell counting using a Burker 
chamber. Monovariate and bivariate cell cycle analyses 
were performed as described in [38, 39]. Briefly, DNA 
content was measured by propidium iodide (50mg/ml) 
staining of and cytofluorimetry. Cells were pulsed with 
10mM bromodeoxyuridine (BrdU, Sigma-Aldrich) for 
30min at 37°C and BrdU incorporation was detected by 
cytofluorimetry using an anti-BrdU antibody (Becton 
Dickinson).
Transfection assays
For details on transfection experiments see 
Supplementary Materials and Methods.
Plasmid constructs
For details on plasmid construction see 
Supplementary Materials and Methods.
RNA extraction and qRT-PCR
Total RNA from cultured cells was isolated by 
TRIzol (Invitrogen) according to the manufacturer 
instructions. RNA from FFPE tissues (three 15μm-
thick sections for each sample) was isolated using 
the RecoverAll isolation kit (Ambion) following the 
manufacturer’s protocol.
Mature miR-196b and the endogenous control 
RNU6B were reverse transcribed and detected by real-
time (qRT-PCR) with TaqMan® microRNA assays 
(Applied Biosystems) following the manufacturer’s 
protocol. Synthesis of cDNA was done starting from 
3 μg of total RNA using M-MLV reverse transcriptase 
(Promega), oligo(dT) and random primers. In all qRT-PCR 
experiments, the relative quantification was performed 
according to the ΔΔCt method [40]. Oligonucleotides used 
are listed in Supplementary Materials and Methods.
Protein extracts and immunoblotting
For details on immunoblotting and protein extraction 
see Supplementary Materials and Methods.
Immunostainings
Paraffin sections were rehydrated following ethanol 
series and antigen retrieval was performed in Tris-HCl 
10mM, EDTA 1mM in pressure cooker at 121°C for 
20min. Slides were bleached in 0,3% H2O2 and blocked in 
2%BSA, 0,1%TWEEN-20. Sections were then incubated 
overnight with primary GATA6 antibody (1:100, AF1700, 
R&D System) at 4°C and for one hour with biotinylated 
anti-goat antibody (1:200) at room temperature, followed 
by 50min incubation with AB complex (Vector Vectastain 
Elite kit). Signal was visualized with diaminobenzidine 
and counterstained with Harris hematoxylin according to 
the standard procedure.
Bioinformatics and statistical analyses
For details on statistics and bioinformatics see 
Supplementary Materials and Methods.
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